Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Helus Pharma (Nasdaq: HELP) said it completed enrollment in its Phase 3 APPROACH study of HLP003, an investigational adjunctive treatment for major depressive disorder, ahead of schedule. The company reported 223 enrolled participants and expects topline data in Q4 2026. Phase 2 results cited include ~23-point MADRS reduction and 100% response/71% remission.
How this was made
The 30-second read
Why it matters
Completing enrollment ahead of schedule reduces execution risk and increases confidence in the planned Q4 2026 topline readout, which is the next major decision point for HLP003’s Phase 3 program.
Market read
This is a concrete Phase 3 execution milestone for HELP’s lead asset, with topline timing reiterated for Q4 2026.
What to watch
The release does not disclose interim results, safety signals, or any changes to endpoints/sample characteristics beyond enrollment completion, so traders should avoid extrapolating efficacy from execution milestones alone.
Background
Helus Pharma is running a Phase 3 PARADIGM Program for HLP003, with APPROACH as the first pivotal study and EMBRACE as the second, plus EXTEND for long-term safety/durability and potential redosing.
Ticker impact
Helus Pharma (HELP) says it completed enrollment in its APPROACH Phase 3 pivotal study of HLP003 for adjunctive MDD treatment, ahead of schedule.
Near-term upside bias versus peers on reduced execution risk, with follow-through contingent on Q4 2026 efficacy and safety results.
The article provides a concrete operational milestone (enrollment completed ahead of schedule) and reiterates topline timing (Q4 2026), which can support sentiment and reduce probability of timeline slippage. However, it does not provide new efficacy/safety results, limiting magnitude.
Market effects
Supports the broader interventional psychiatry narrative and may improve sentiment toward serotonergic agonist/deuterated psilocin analog development programs.
Limited direct regional impact; primarily US-listed clinical-stage biotech sentiment.
Moderate, as Phase 3 progress in depression therapeutics can influence global peer sentiment even without new data.
Counterpoint
Enrollment completion can be largely procedural; without new efficacy or safety data, the market may quickly refocus on the probability-weighted outcome of Q4 2026 topline.
Key entities
- companyHelus Pharma
Clinical-stage pharmaceutical company developing HLP003 for adjunctive treatment of major depressive disorder.
- drug_candidateHLP003
Investigational deuterated psilocin analogue with FDA Breakthrough Therapy Designation, being tested as adjunctive therapy in Phase 3.
- clinical_trialAPPROACH
Phase 3 pivotal study of HLP003 in adults with moderate to severe MDD on stable antidepressant regimens but inadequate response.
- clinical_trialEXTEND
Long-term extension study intended to evaluate safety, durability, and potential redosing.
